flarecactus2

Somatropin treatment should be discontinued if the quality of life has not improved sufficiently by 9 months. Further mortality data from the European SAGhE study will be available by the end of 2012, and the CHMP considered an analysis of these results to be essential to address any concerns raised by the French study. The CHMP concluded that the French SAGhE study had significant methodological limitations and that the results could not be co

0 entry(s) Showing 1 to 20

Case Number Domain(s) Complainant Respondent Ruleset Status